Can analysts adopt a bullish outlook for Zoetis Inc. (NYSE:ZTS)?

Zoetis Inc. (NYSE:ZTS) Logo
Investors sentiment decreased to 1.08 in Q2 2019. Its down 0.10, from 1.18 in 2019Q1. It is negative, as 43 investors sold Zoetis Inc. shares while 278 reduced holdings. 100 funds opened positions while 248 raised stakes. 413.40 million shares or 0.16% less from 414.06 million shares in 2019Q1 were reported.
Evercore Wealth Mgmt has invested 0.04% in Zoetis Inc. (NYSE:ZTS). Blb&B Advsrs Ltd Company holds 62,938 shares. Ar Asset Mgmt Inc, a California-based fund reported 34,076 shares. 40,636 are owned by Covington Capital. Wendell David Assocs Inc reported 0.21% in Zoetis Inc. (NYSE:ZTS). Kentucky Retirement System has invested 0.22% in Zoetis Inc. (NYSE:ZTS). Harding Loevner Limited Partnership has 0% invested in Zoetis Inc. (NYSE:ZTS) for 380 shares. 3,539 are held by Whittier. Metropolitan Life Company Ny invested 0.2% of its portfolio in Zoetis Inc. (NYSE:ZTS). The Pennsylvania-based Glenmede Trust Na has invested 0.03% in Zoetis Inc. (NYSE:ZTS). Japan-based Meiji Yasuda Asset Mgmt Limited has invested 0.23% in Zoetis Inc. (NYSE:ZTS). Moreover, Ww Asset Mgmt has 0.18% invested in Zoetis Inc. (NYSE:ZTS). Tiverton Asset Management Ltd Liability Com has 0.09% invested in Zoetis Inc. (NYSE:ZTS). Strategy Asset Managers Ltd Liability holds 0.22% or 6,965 shares. Polaris Greystone Fincl Gp Lc reported 1.51% of its portfolio in Zoetis Inc. (NYSE:ZTS).

Zoetis Inc. (NYSE:ZTS) Ratings Coverage

Among 8 analysts covering Zoetis (NYSE:ZTS), 4 have Buy rating, 0 Sell and 4 Hold. Therefore 50% are positive. Zoetis has $132 highest and $100 lowest target. $118.63’s average target is -2.00% below currents $121.05 stock price. Zoetis had 11 analyst reports since March 19, 2019 according to SRatingsIntel. The stock of Zoetis Inc. (NYSE:ZTS) has “Buy” rating given on Tuesday, June 25 by Craig Hallum. Stifel Nicolaus maintained the shares of ZTS in report on Monday, July 22 with “Buy” rating. The rating was maintained by BMO Capital Markets on Thursday, May 9 with “Market Perform”. On Wednesday, March 20 the stock rating was initiated by UBS with “Hold”. The firm has “Outperform” rating given on Tuesday, April 2 by Credit Suisse. Bank of America downgraded Zoetis Inc. (NYSE:ZTS) on Monday, July 1 to “Neutral” rating. The rating was maintained by SunTrust with “Hold” on Tuesday, August 13. The firm has “Hold” rating by SunTrust given on Tuesday, March 19. Below is a list of Zoetis Inc. (NYSE:ZTS) latest ratings and price target changes.

13/08/2019 Broker: SunTrust Rating: Hold Old Target: $120.0000 New Target: $130.0000 Maintain
22/07/2019 Broker: Stifel Nicolaus Rating: Buy Old Target: $110.0000 New Target: $130.0000 Maintain
01/07/2019 Broker: Bank of America Old Rating: Buy New Rating: Neutral Old Target: $111.0000 New Target: $120.0000 Downgrade
25/06/2019 Broker: Craig Hallum Rating: Buy New Target: $132 Maintain
11/06/2019 Broker: Barclays Capital Rating: Overweight New Target: $120.0000 Initiates Coverage On
09/05/2019 Broker: BMO Capital Markets Rating: Market Perform Old Target: $101.0000 New Target: $105.0000 Maintain
07/05/2019 Broker: BidaskScore Rating: Buy Upgrade
03/05/2019 Broker: Gabelli Old Rating: Buy New Rating: Hold Downgrade
02/04/2019 Broker: Credit Suisse Old Rating: Outperform New Rating: Outperform Old Target: $102 New Target: $112 Maintain
20/03/2019 Broker: UBS Rating: Hold New Target: $100 Initiate

The stock decreased 0.53% or $0.64 during the last trading session, reaching $121.05. About 2.01M shares traded or 3.79% up from the average. Zoetis Inc. (NYSE:ZTS) has risen 35.98% since September 13, 2018 and is uptrending. It has outperformed by 35.98% the S&P500.

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines and vaccines for livestock and companion animals in the United States and internationally. The company has market cap of $57.81 billion. It offers anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; and parasiticides that prevent or eliminate external and internal parasites, such as fleas, ticks, and worms. It has a 42.77 P/E ratio. The firm also provides medicated feed additives that offer medicines to livestock; and other pharmaceutical products, including pain and sedation, oncology, antiemetic, allergy and dermatology, and reproductive products.

More notable recent Zoetis Inc. (NYSE:ZTS) news were published by: Fool.com which released: “3 Ideas to Make Your Portfolio Recession-Resistant – The Motley Fool” on September 10, 2019, also Seekingalpha.com with their article: “Zoetis combo heartworm med shows efficacy in studies – Seeking Alpha” published on September 09, 2019, Finance.Yahoo.com published: “What Are Analysts Saying About Zoetis Inc.’s (NYSE:ZTS) Growth? – Yahoo Finance” on July 15, 2019. More interesting news about Zoetis Inc. (NYSE:ZTS) were released by: Finance.Yahoo.com and their article: “Investors Who Bought Zoetis (NYSE:ZTS) Shares Five Years Ago Are Now Up 234% – Yahoo Finance” published on May 21, 2019 as well as Fool.com‘s news article titled: “How Will Johnson & Johnson’s Opioid Case Ruling Impact Big Pharma Stocks? – The Motley Fool” with publication date: September 05, 2019.

Zoetis Inc. (NYSE:ZTS) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.